New trial aims to bring targeted lymphoma drugs to minority patients
NCT ID NCT06859008
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 trial is testing a combination of two targeted drugs, zanubrutinib and sonrotoclax, in people from underrepresented racial and ethnic groups who have relapsed or refractory B-cell non-Hodgkin lymphoma. The study aims to see if this treatment is feasible and safe for these patients, who often face barriers to accessing clinical trials. Participants will take the drugs orally and be monitored for side effects and how long they stay on treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zanubrutinib and sonrotoclax
What this could lead to
If successful, this could show that a targeted drug combination is safe and feasible for minority patients with hard-to-treat B-cell lymphomas, potentially improving access and outcomes.
What could go wrong
This is a very early phase 1 trial with only 37 participants, so it is primarily testing feasibility and safety, not effectiveness. The results may not apply to all patients or lead to a new standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact